Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 0.85
Emergent BioSolutions Inc. reported the quarter and year ended December 31, 2023 results: revenue $1,049.3, net income $ (760.5), EPS $ (14.85). Guidance raised.
- Period
- the quarter and year ended December 31, 2023
- Revenue
- $1,049.3
- Net income
- $ (760.5)
- EPS
- $ (14.85)
- Guidance
- raised
- Result
- reported results
Exact text from the filing
Gross Margin % (2) 32 % 48 % * % change is greater than +/- 100% Full Year 2023 vs. Full Year 2022 ($ in millions, except per share amounts) 2023 2022 % Change Total Revenues $ 1,049.3 $ 1,117.5 (6) % Net Loss $ (760.5) $ (211.6) * Net Loss per Diluted Share $ (14.85) $ (4.22) * Adjusted Net Loss (2) $ (319.0) $ (99.7) * Adjusted Net Loss per Diluted Share (2) $
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Emergent BioSolutions Inc. amended Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement with Wells Fargo Bank, National Association, as administrative agent, and certain lenders valued at $270 million (effective 2024-02-29).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- Wells Fargo Bank, National Association, as administrative agent, and certain lenders
- Value
- $270 million
- Effective
- 2024-02-29
Exact text from the filing
On February 29, 2024, Emergent BioSolutions Inc. (the “Company”) entered into a Forbearance Agreement and Sixth Amendment to Amended and Restated Credit Agreement (the “Forbearance Agreement and Amendment”), among the Company, as borrower, certain subsidiaries of the Company, as guarantors, Wells Fargo Bank, National Association, as administrative agent (in such capacity, the “Administrative Agent”) and certain lenders party thereto (the “Lenders”).
View on SEC.gov